AssetIndicationPre-ClinicalIND-Enabling StudiesPhase 1Phase 2Phase 3
OK-101
Dry Eye
*Not requiredAnticipated start date Q1/2023

Uveitis

Allergic Conjunctivitis

Ocular Pain

OK-201
Discovery Program

OK-101 Anticipated IND Submission date Q4, 2022
* Ocular topical drug delivery
DrugIndicationStage
OK-101
Dry Eye IND-Enabling Studies*
Uveitis Pre-Clinical
Allergic Conjunctivitis Pre-Clinical
Ocular Pain Pre-Clinical
OK-201
Discovery Program
*OK-101 Anticipated IND Submission date Q4, 2022
Anticipated Phase 2 start date Q1, 2023

OK-101 Development Timeline